Marrow On The Move™ will be different again this year due to COVID. It will be held on Wednesday, July 28, 2021 from 6:30-7:30 pm. Watch for information.
This annual event brings people together to celebrate the lives of those who have received a transplantation or cellular infusion for a life-threatening blood disease. Doctors at the University of Minnesota Adult Blood and Marrow Transplant and Cellular Therapy Program (BMTCT) Program are world-renowned experts in blood and bone marrow transplantation and cellular therapy. They have provided life-saving treatments for thousands of individuals who have battled blood diseases such as leukemia, lymphoma, aplastic anemia, and immune deficiency disorders. Marrow On The Move™ celebrates our patients who have battled a blood disease, remembers those who have lost their lives, and empowers individuals and communities to fight back against diseases that take too much.
Marrow On The Move™ brings together the BMTCT community—including families, friends, blood and marrow donors, and care providers—as they celebrate the victories they have attained in fighting debilitating blood diseases. The day will feature activities including a walk/run/ride tailored to allow the participation of people at all levels of physical fitness. The event will also feature a campaign to raise funds for operational expenses for next year's event and for BMTCT research. Doctors in the adult BMT Program are engaged in cutting-edge research at the University of Minnesota. Funds raised during Marrow On The Move™ will support research to improve the care and outcomes of our BMTCT patients.
Our patients come together in small support groups organized by our BMTCT social workers. Patients deeply appreciate these support groups and often report how great it is to realize that "I am not alone." For patients in the first year of treatment, these support groups allow them to see that others have gone through the same experiences and are thriving years later. Moreover, patients who have survived for longer than a year after treatment are happy for the opportunity to share their experiences and encourage those who are still recovering. After hearing about Marrow On The Move™, one individual in a support group said, "I always have a goal to look forward to. Now I have something to look forward to next summer!"
- Dr. Marie Hu
“Disparities in CAR-T referral and utilization for patients with diffuse large B-cell lymphoma”
- Dr. Fiona He
"Cellular senescence as a biomarker of frailty and predictor of toxicity"
- Dr. Murali Janakiram
"Study of immune reconstitution in multiple myeloma after ASCT"
- Dr. Joseph Maakaron
"Neurotoxicity prophylaxis with intrathecal dexamethasone and simvastatin"
- Dr. John Schempf
"Impact of dysglycemia on transplant outcomes in patients undergoing autologous and allogeneic hematopoietic stem cell transplantation"
- Dr. Najla El Jurdi
"Skin Graft-versus-Host Disease and Host Antimicrobial Defense Peptides: Identifying Key Mechanisms Orchestrating Mucosal Barrier Dysfunction and Microbial Dysbiosis"
- Drs. Mukta Arora and Todd DeFor
"Improving outcomes in elderly allogeneic hematopoietic cell transplant (HCT) recipients"
- Dr. Shernan Holtan
"Improving self-efficacy and resolving inflammation in allogeneic hematopoietic cell transplant survivors through personalized strength programming: A pilot study"
- Dr. Armin Rashidi
"Serum biomarkers of gut barrier radio-sensitivity to predict bloodstream infection in allogeneic hematopoietic cell transplant recipients receiving high-dose total body irradiation-based conditioning"
- Dr. Veronika Bachanova
"Genetic characterization of Ph-like ALL in patients relapsing after allogeneic HCT"
- Dr. Nelli Bejanyan
"Virus-specific immune cell reconstitution after reduced intensity conditioning double umbilical cord blood and matched sibling donor peripheral blood hematopoietic cell transplantation"
- Dr. Shernan Holtan
"Epidermal Growth Factor Receptor Signaling in Acute GVHD: Hot or Not?"
- Dr. Armin Rashidi
"Association between TNFa rs361525 polymorphism and grade II-IV acute Graft-versus-host disease"